-+ 0.00%
-+ 0.00%
-+ 0.00%
Akeso Says FDA Complete Response Letter May Explain Unusual Share Price Moves
Share
Listen to the news
Akeso Says FDA Complete Response Letter May Explain Unusual Share Price Moves
  • Akeso said Nov. 16, 2026, an FDA complete response letter for ivonescimab may have caused unusual share-price movements.
  • Summit Therapeutics disclosed the letter Nov. 15 concerning ivonescimab's biologics license application based on the HARMONi study.
  • Following inquiries, Akeso identified no other reasons for the movements or undisclosed inside information requiring disclosure.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261116-12413539), on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending